Similar companies
Income Statement (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Revenue | 1.02B | 615.5% |
| Gross Profit | 8M | 65.2% |
| Cost of Revenue | 1.01B | 747.1% |
| Operating expense | 268M | 71.2% |
| Net Income | -200M | 75.8% |
| EBITDA | -135M | 82.2% |
Balance Sheet (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Total Assets | 12.1B | 1% |
| Total Liabilities | 2.81B | 7.4% |
| Total Equity | 9.33B | 0.7% |
| Shares Outstanding | 390M | 0.5% |
Cash Flow (USD)
| Q3 '25 | QoQ | |
|---|---|---|
| Cash from operations | -847M | 7.8% |
| Cash from investing | 700M | 24.1% |
| Cash from financing | -1M | 111.1% |
EPS
Financial Highlights for Moderna in Q3 '25
Moderna reported a revenue of 1.02B, which is a 615.5% change from the previous quarter. An increase in revenue typically indicates growing demand for the company's products or services. This positive change in revenue is a good sign, suggesting that the company's sales are moving in the right direction.
Gross Profit stood at 8M, marking a -65.2% change since the last quarter. Gross profit showcases the efficiency in production and sales processes.
Cost of Revenue was 1.01B, a 747.1% difference from the previous quarter. A rising cost of revenue may suggest increased production or sales costs, which can impact margins. However, if accompanied by a proportionate rise in revenue, it could indicate scaling operations.
Operating Expenses for this period were 268M, showing a -71.2% change from the last quarter. Operating expenses cover the costs of running daily business operations. A significant increase might indicate inefficiencies or investments in growth, while a decrease could suggest cost-saving measures or potential underinvestment in key areas.
Net Income for the quarter was -200M, showing a 75.8% change from the prior quarter. Net income provides a clear picture of the company's profitability after all expenses. An increase suggests the company is becoming more profitable, while a decrease may raise concerns about the company's financial health, unless there are specific one-time costs or investments.
The company's EBITDA for the quarter was -135M, showing a 82.2% change from the previous period. EBITDA gives insight into the company's operational profitability, excluding non-operating expenses like interest and taxes. A rising EBITDA indicates strong operational performance, while a declining EBITDA may signal operational challenges or increased costs.
Moderna faced some challenges this quarter with a decline in one or more of the key metrics: revenue, gross profit, or net income. An increase in the cost of revenue, higher than the revenue growth, suggests potential margin pressures.
